Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | Could immunotherapy plus an ADC replace the standard of care in NSCLC?

Molly Li, MBBS, MRCP, FHKCP, FHKAM, The Chinese University of Hong Kong, Hong Kong, China, comments on the potential of immunotherapy (IO) plus an antibody-drug conjugate (ADC) in replacing the standard of care in non-small cell lung cancer (NSCLC). The Phase II CITADEL (NCT06055465) trial hypothesized a 20% improvement in pathological complete response (pCR) rate with IO plus sacituzumab govitecan compared to the KEYNOTE-671 study (NCT03425643). However, a larger trial is needed to validate this concept after an initial signal is achieved. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Ultimately, I mean to replace the standard of care, we do need a phase 3 trial, RCT, that head-to-head compares IO plus a novel ADC versus perioperative IO chemotherapy. And before we embark on such a large trial, usually we start with a phase two design. And in our study, we hypothesized that the IO plus cetuximab would lead to a 20% improvement in pCR rate compared to the pCR rate in the KEYNOTE 671 study...

Ultimately, I mean to replace the standard of care, we do need a phase 3 trial, RCT, that head-to-head compares IO plus a novel ADC versus perioperative IO chemotherapy. And before we embark on such a large trial, usually we start with a phase two design. And in our study, we hypothesized that the IO plus cetuximab would lead to a 20% improvement in pCR rate compared to the pCR rate in the KEYNOTE 671 study. So we hypothesized that there’s an improvement from 18% pCR to 38% pCR, and then with one-sided alpha 0.05 power 0.8, we calculated the sample size of 37 in this regard. However, after achieving a signal, we do need an RCT to validate this concept.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.